23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › SERES THERAPEUTICS INC. › 2023-2024

SERES THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and SERES THERAPEUTICS INC.’s Form 8-K, filed April 8, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 7Ballot items
  • 112Asset managers, any item
  • 865Fund votes
  • April 4, 2024Meeting date

Results at a glance

Meeting of April 4, 2024: 7 items on SERES THERAPEUTICS INC.’s Form 8-K, filed April 8, 2024: 1 approved · 6 passed (calculated).

Dissent

High dissent: 1 shareholder proposal (63.7% support).

Significant dissent: 2 directors (38.1%, 35.2% against); 1 say-on-pay vote (64.6% support).

Notable dissent: 2 other board items (20.8%, 18.9% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025

Explore SERES THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by SERES THERAPEUTICS INC.

These tallies are SERES THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed April 8, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

SERES THERAPEUTICS INC. — official shareholder meeting results, meeting held April 4, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Paul R. Biondi 53,477,829---- 29,111,82921,764,552 65%Passed (calculated)—
Elect Director: Kurt C. Graves 51,107,660---- 31,481,99821,764,552 62%Passed (calculated)—
2. Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024 100,843,5502,910,775599,885 --0 97%Passed (calculated)—
3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers 52,923,69929,004,971660,988 --21,764,552 65%Passed (calculated)—
4. Approval of an amendment to the Company's Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 240,000,000 to 360,000,000 shares 81,471,93421,346,1401,536,136 --0 79%Passed (calculated)—
5. Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there were not sufficient votes at the time of the Annual Meeting to approve Item 4 83,248,72919,390,1951,715,286 --0 81%Passed (calculated)—
6. Stockholder proposal on Simple Majority Vote 52,117,62429,641,877830,157 --21,764,552 64%Approved—

Source: SERES THERAPEUTICS INC., Form 8-K, filed with the SEC on April 8, 2024 — read the filing on EDGAR.

How asset managers voted at the SERES THERAPEUTICS INC. 2023-2024 meeting

112 asset managers disclosed a vote on at least one SERES THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Kurt C. Graves

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

62% Majority: yes · of votes cast

FOR 62%WITHHELD
FOR: 51,107,660WITHHELD: 31,481,998
Details: description as filed, official tally, votes by 32 asset managers

Description as filed by funds: Election of Directors: Kurt C. Graves

SERES THERAPEUTICS INC.’s own tally for this item (“Elect Director: Kurt C. Graves”): 51,107,660 for, 31,481,998 withheld, per its Form 8-K filed April 8, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 62% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 6,843,861 for, 11,391,511 withheld, 18,442 abstained.

FORWITHHOLD
FOR: 6,843,861ABSTAIN: 18,442WITHHOLD: 11,391,511
Largest asset managers voting on “Election of Directors: Kurt C. Graves” at SERES THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity1,018,2480 010,615,535Mixed
Vanguard4,073,1900 00For
BlackRock1,168,1140 00For
Charles Schwab390,8530 00For
SIT MUTUAL FUNDS INC00 0246,775Withhold
Equitable39,4640 0127,660Mixed
BRIDGEWAY FUNDS INC00 0150,000Withhold
Lincoln Financial00 080,000Withhold
QUANTITATIVE MASTER SERIES LLC54,7300 00For
Principal Exchange-Traded Funds00 048,917Withhold
Northern Trust00 043,623Withhold
Pacific Life34,8780 00For
Voya33,0610 00For
Bridge Builder Trust24,4680 00For
John Hancock00 18,4420Abstain
DWS00 015,065Withhold
Victory Capital00 012,948Withhold
Principal00 012,159Withhold
AIG/SunAmerica00 011,365Withhold
State Street00 08,462Withhold
Calvert00 08,033Withhold
Morgan Stanley3,8660 00For
ProShares00 03,755Withhold
PENN SERIES FUNDS INC00 03,600Withhold
SEI2,3000 00For

Showing the 25 largest of 32 asset managers. All 32 are in the interactive database (link above).

Elect Director: Paul R. Biondi

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

65% Majority: yes · of votes cast

FOR 65%WITHHELD
FOR: 53,477,829WITHHELD: 29,111,829
Details: description as filed, official tally, votes by 32 asset managers

Description as filed by funds: Election of Directors: Paul R. Biondi

SERES THERAPEUTICS INC.’s own tally for this item (“Elect Director: Paul R. Biondi”): 53,477,829 for, 29,111,829 withheld, per its Form 8-K filed April 8, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 65% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 6,981,326 for, 11,254,046 withheld, 18,442 abstained.

FORWITHHOLD
FOR: 6,981,326ABSTAIN: 18,442WITHHOLD: 11,254,046
Largest asset managers voting on “Election of Directors: Paul R. Biondi” at SERES THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity1,018,2480 010,615,535Mixed
Vanguard4,073,1900 00For
BlackRock1,168,1140 00For
Charles Schwab390,8530 00For
SIT MUTUAL FUNDS INC00 0246,775Withhold
Equitable39,4640 0127,660Mixed
BRIDGEWAY FUNDS INC00 0150,000Withhold
Lincoln Financial80,0000 00For
QUANTITATIVE MASTER SERIES LLC54,7300 00For
Principal Exchange-Traded Funds00 048,917Withhold
Northern Trust43,6230 00For
Pacific Life34,8780 00For
Voya33,0610 00For
Bridge Builder Trust24,4680 00For
John Hancock00 18,4420Abstain
DWS00 015,065Withhold
Victory Capital00 012,948Withhold
Principal00 012,159Withhold
AIG/SunAmerica00 011,365Withhold
State Street8,4620 00For
Calvert00 08,033Withhold
Morgan Stanley3,8660 00For
ProShares00 03,755Withhold
PENN SERIES FUNDS INC3,6000 00For
SEI2,3000 00For

Showing the 25 largest of 32 asset managers. All 32 are in the interactive database (link above).

Approval of an amendment to the Company's Restated Certificate of Incorporation to increase the number of authorized…

Calculated outcomeCAPITAL STRUCTUREPassed (calculated)

Combines 2 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%AGAINST
FOR: 81,471,934AGAINST: 21,346,140
Details: description as filed, official tally, votes by 32 asset managers

Description as filed by funds: APPROVAL OF AN AMENDMENT TO OUR RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 240,000,000 TO 360,000,000.

SERES THERAPEUTICS INC.’s own tally for this item (“4. Approval of an amendment to the Company's Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 240,000,000 to 360,000,000 shares”): 81,471,934 for, 21,346,140 against, per its Form 8-K filed April 8, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 79% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 18,253,814 for.

FOR
FOR: 18,253,814
Largest asset managers voting on “APPROVAL OF AN AMENDMENT TO OUR RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHA” at SERES THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity11,633,7830 00For
Vanguard4,073,1900 00For
BlackRock1,168,1140 00For
Charles Schwab390,8530 00For
SIT MUTUAL FUNDS INC246,7750 00For
Equitable167,1240 00For
BRIDGEWAY FUNDS INC150,0000 00For
Lincoln Financial80,0000 00For
QUANTITATIVE MASTER SERIES LLC54,7300 00For
Principal Exchange-Traded Funds48,9170 00For
Northern Trust43,6230 00For
Pacific Life34,8780 00For
Voya33,0610 00For
Bridge Builder Trust24,4680 00For
John Hancock18,4420 00For
DWS15,0650 00For
Victory Capital12,9480 00For
Principal12,1590 00For
AIG/SunAmerica11,3650 00For
State Street8,4620 00For
Calvert8,0330 00For
Morgan Stanley3,8660 00For
ProShares3,7550 00For
PENN SERIES FUNDS INC3,6000 00For
SEI2,3000 00For

Showing the 25 largest of 32 asset managers. All 32 are in the interactive database (link above).

Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there were not…

Calculated outcomeCORPORATE GOVERNANCEPassed (calculated)

Combines 2 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%AGAINST
FOR: 83,248,729AGAINST: 19,390,195
Details: description as filed, official tally, votes by 32 asset managers

Description as filed by funds: APPROVAL OF AN ADJOURNMENT OF THE ANNUAL MEETING, IF NECESSARY, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT SUFFICIENT VOTES AT THE TIME OF THE ANNUAL MEETING TO APPROVE PROPOSAL 4.

SERES THERAPEUTICS INC.’s own tally for this item (“5. Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there were not sufficient votes at the time of the Annual Meeting to approve Item 4”): 83,248,729 for, 19,390,195 against, per its Form 8-K filed April 8, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 81% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 18,159,918 for, 93,896 against.

FOR
FOR: 18,159,918AGAINST: 93,896
Largest asset managers voting on “APPROVAL OF AN ADJOURNMENT OF THE ANNUAL MEETING, IF NECESSARY, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT” at SERES THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity11,633,7830 00For
Vanguard4,073,1900 00For
BlackRock1,168,1140 00For
Charles Schwab390,8530 00For
SIT MUTUAL FUNDS INC246,7750 00For
Equitable167,1240 00For
BRIDGEWAY FUNDS INC150,0000 00For
Lincoln Financial080,000 00Against
QUANTITATIVE MASTER SERIES LLC54,7300 00For
Principal Exchange-Traded Funds48,9170 00For
Northern Trust43,6230 00For
Pacific Life34,8780 00For
Voya33,0610 00For
Bridge Builder Trust24,4680 00For
John Hancock18,4420 00For
DWS15,0650 00For
Victory Capital12,9480 00For
Principal12,1590 00For
AIG/SunAmerica11,3650 00For
State Street08,462 00Against
Calvert8,0330 00For
Morgan Stanley3,8660 00For
ProShares3,7550 00For
PENN SERIES FUNDS INC03,600 00Against
SEI2,3000 00For

Showing the 25 largest of 32 asset managers. All 32 are in the interactive database (link above).

Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers

Calculated outcomeFund totals may overlapCOMPENSATIONPassed (calculated)

Combines 8 wordings of this item as funds reported it.

65% Majority: yes · of votes cast

FOR 65%AGAINST
FOR: 52,923,699AGAINST: 29,004,971

Prior year: 99.4% for (June 22, 2023 meeting) ▼ 34.8 pts

Details: description as filed, official tally, votes by 111 asset managers

Description as filed by funds: Approval, on an advisory (non- binding) basis, of the compensation of our named executive officers.

SERES THERAPEUTICS INC.’s own tally for this item (“3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers”): 52,923,699 for, 29,004,971 against, per its Form 8-K filed April 8, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 65% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 32 asset managers voting on “Approval, on an advisory (non- binding) basis, of the compensation of our named executive officers.” at SERES THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity1,030,74810,603,035 00Mixed
Vanguard4,073,1900 00For
BlackRock1,168,1140 00For
Charles Schwab390,8530 00For
SIT MUTUAL FUNDS INC246,7750 00For
Equitable167,1240 00For
BRIDGEWAY FUNDS INC0150,000 00Against
Lincoln Financial80,0000 00For
QUANTITATIVE MASTER SERIES LLC54,7300 00For
Principal Exchange-Traded Funds48,9170 00For
Northern Trust43,6230 00For
Pacific Life34,8780 00For
Voya33,0610 00For
Bridge Builder Trust24,4680 00For
John Hancock18,4420 00For
DWS15,0650 00For
Victory Capital12,9480 00For
Principal12,1590 00For
AIG/SunAmerica11,3650 00For
State Street8,4620 00For
Calvert08,033 00Against
Morgan Stanley3,8660 00For
ProShares3,7550 00For
PENN SERIES FUNDS INC3,6000 00For
SEI2,3000 00For

Fund voting reports, all 32 managers: 7,492,746 for, 10,761,068 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 92 asset managers voting on “Approval, on an advisory (non- binding) basis, of the compensation of our named executive officers.” at SERES THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Flagship Pioneering Inc.23,117,0450 00For
Fidelity018,375,792 00Against
Hudson Bay Capital Management LP4,048,1790 00For
BlackRock2,309,3455,136 00For
GEODE CAPITAL MANAGEMENT, LLC1,118,4820 00For
State Street1,043,683130 00For
Woodline Partners LP698,9990 00For
MELLON INVESTMENTS Corp485,9150 00For
Charles Schwab390,8530 00For
Handelsbanken Fonder AB329,9260 00For
Point72294,3270 00For
Graham Capital Management, L.P.234,3430 00For
T. Rowe Price202,9520 00For
DE Shaw173,8510 00For
AllianceBernstein127,6600 00For
Vanguard123,0340 00For
SIT INVESTMENT ASSOCIATES INC95,4250 00For
Janney Montgomery Scott LLC75,0980 00For
PRINCIPAL GLOBAL INVESTORS61,0760 00For
Crestwood Advisors Group, LLC60,4330 00For
Northern Trust52,448149 00For
EDGEWOOD MANAGEMENT LLC50,0000 00For
Rhumbline43,26250 00For
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM040,734 00Against
JPMorgan39,2550 00For

Institutional-manager reports, all 92 managers: 35,506,722 for, 18,455,050 against. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 100,843,550AGAINST: 2,910,775

Prior year: 99.8% for (June 22, 2023 meeting) ▼ 2.6 pts

Details: description as filed, official tally, votes by 32 asset managers

Description as filed by funds: Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

SERES THERAPEUTICS INC.’s own tally for this item (“2. Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024”): 100,843,550 for, 2,910,775 against, per its Form 8-K filed April 8, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 18,095,503 for, 158,311 against.

FOR
FOR: 18,095,503AGAINST: 158,311
Largest asset managers voting on “Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for ” at SERES THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity11,633,7830 00For
Vanguard4,073,1900 00For
BlackRock1,168,1140 00For
Charles Schwab390,8530 00For
SIT MUTUAL FUNDS INC246,7750 00For
Equitable167,1240 00For
BRIDGEWAY FUNDS INC0150,000 00Against
Lincoln Financial80,0000 00For
QUANTITATIVE MASTER SERIES LLC54,7300 00For
Principal Exchange-Traded Funds48,9170 00For
Northern Trust43,6230 00For
Pacific Life34,8780 00For
Voya33,0610 00For
Bridge Builder Trust24,4680 00For
John Hancock18,4420 00For
DWS15,0650 00For
Victory Capital12,9480 00For
Principal12,1590 00For
AIG/SunAmerica11,3650 00For
State Street8,4620 00For
Calvert08,033 00Against
Morgan Stanley3,8660 00For
ProShares3,7550 00For
PENN SERIES FUNDS INC3,6000 00For
SEI2,3000 00For

Showing the 25 largest of 32 asset managers. All 32 are in the interactive database (link above).

Stockholder proposal on Simple Majority Vote

Official resultCORPORATE GOVERNANCEReported outcome: Approved

Proposed by: Kenneth Steiner

Combines 3 wordings of this item as funds reported it.

64% Approved · of votes cast

FOR 64%AGAINST
FOR: 52,117,624AGAINST: 29,641,877
Details: description as filed, official tally, votes by 32 asset managers

Description as filed by funds: A STOCKHOLDER PROPOSAL ON SIMPLE MAJORITY VOTE, IF PROPERLY PRESENTED.

SERES THERAPEUTICS INC.’s own tally for this item (“6. A stockholder proposal on Simple Majority Vote”): 52,117,624 for, 29,641,877 against — passed, per its Form 8-K filed April 8, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Item 6 – A stockholder proposal on Simple Majority Vote.”
Support: 64% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 18,253,814 for.

FOR
FOR: 18,253,814
Largest asset managers voting on “A STOCKHOLDER PROPOSAL ON SIMPLE MAJORITY VOTE, IF PROPERLY PRESENTED.” at SERES THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity11,633,7830 00For
Vanguard4,073,1900 00For
BlackRock1,168,1140 00For
Charles Schwab390,8530 00For
SIT MUTUAL FUNDS INC246,7750 00For
Equitable167,1240 00For
BRIDGEWAY FUNDS INC150,0000 00For
Lincoln Financial80,0000 00For
QUANTITATIVE MASTER SERIES LLC54,7300 00For
Principal Exchange-Traded Funds48,9170 00For
Northern Trust43,6230 00For
Pacific Life34,8780 00For
Voya33,0610 00For
Bridge Builder Trust24,4680 00For
John Hancock18,4420 00For
DWS15,0650 00For
Victory Capital12,9480 00For
Principal12,1590 00For
AIG/SunAmerica11,3650 00For
State Street8,4620 00For
Calvert8,0330 00For
Morgan Stanley3,8660 00For
ProShares3,7550 00For
PENN SERIES FUNDS INC3,6000 00For
SEI2,3000 00For

Showing the 25 largest of 32 asset managers. All 32 are in the interactive database (link above).

Largest SERES THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 151,009,462 shares outstanding at the time of that meeting.

Fund voting reports: top SERES THERAPEUTICS INC. shareholders by shares voted on “Approval, on an advisory (non- binding) basis, of the compensation of our named executive…”, 2023-2024
#Asset manager % of shares outstanding
1Fidelity 7.70%
2Vanguard 2.70%
3BlackRock 0.77%
4Charles Schwab 0.26%
5SIT MUTUAL FUNDS INC 0.16%
6Equitable 0.11%
7BRIDGEWAY FUNDS INC 0.10%
8Lincoln Financial 0.05%
9QUANTITATIVE MASTER SERIES LLC 0.04%
10Principal Exchange-Traded Funds 0.03%
Institutional-manager reports: top SERES THERAPEUTICS INC. shareholders by shares voted on “Approval, on an advisory (non- binding) basis, of the compensation of our named executive…”, 2023-2024
#Asset manager % of shares outstanding
1Flagship Pioneering Inc. 15.31%
2Fidelity 12.17%
3Hudson Bay Capital Management LP 2.68%
4BlackRock 1.53%
5GEODE CAPITAL MANAGEMENT, LLC 0.74%
6State Street 0.69%
7Woodline Partners LP 0.46%
8MELLON INVESTMENTS Corp 0.32%
9Charles Schwab 0.26%
10Handelsbanken Fonder AB 0.22%

Reported SERES THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

SERES THERAPEUTICS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Entities affiliated with Flagship Pioneering23,117,045 15.31%Proxy statement (DEF 14A), proxy filed March 5, 2024
FMR LLC19,388,579 12.84%Proxy statement (DEF 14A), proxy filed March 5, 2024
Nestlé S.A.7,594,038 5.03%Proxy statement (DEF 14A), proxy filed March 5, 2024
BlackRock, Inc.7,339,454 4.86%Proxy statement (DEF 14A), proxy filed March 5, 2024
Eric D. Shaff2,633,824 1.74%Proxy statement (DEF 14A), proxy filed March 5, 2024
Geode Capital2,132,643 1.41%Form 13F, quarter ended March 31, 2024
State Street1,946,363 1.29%Form 13F, quarter ended March 31, 2024
Millennium Management1,027,552 0.68%Form 13F, quarter ended March 31, 2024
Northern Trust784,693 0.52%Form 13F, quarter ended March 31, 2024
Charles Schwab747,318 0.49%Form 13F, quarter ended March 31, 2024

Percentages above are of 151,009,462 shares outstanding, as reported by SERES THERAPEUTICS INC. on its Form 10-K dated March 1, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At SERES THERAPEUTICS INC.'s shareholder meeting held April 4, 2024, in the 2023-2024 proxy season, 112 asset managers reported votes on at least one of its 7 ballot items in their SEC Form N-PX filings, covering 865 separate fund positions. On the most widely held item on that ballot — Approval, on an advisory (non- binding) basis, of the compensation of our named executive… — FOR was 65% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: SERES THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on April 8, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SERES THERAPEUTICS INC.’s 10-K dated March 1, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

SERES THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025.

Cite this page

Proxy Votes Now, “SERES THERAPEUTICS (MCRB) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/seres-therapeutics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.